Home » Topics » BioWorld Science

BioWorld Science
RSS

Collaborative investigations by Pfizer and Neurogen yield pyrazolopyrimidine NPY antagonists

Sep. 3, 2001

Potent and selective CCR2B receptor antagonist described by GlaxoSmithKline

Sep. 3, 2001

GW-432042: a potent and selective iNOS inhibitor debuts at ACS meeting

Sep. 3, 2001

Antisoma takes on development of promising vascular targeting agent from the CRC

Sep. 3, 2001

FDA accepts Orphan Medical's proposed response plan regarding Xyrem NDA

Sep. 3, 2001

Northfield seeks FDA approval of PolyHeme blood substitute

Sep. 3, 2001

Motorola Life Sciences and SNP Consortium announce key alliance

Sep. 3, 2001

Oxagen and Cerylid initiate gene discovery program for endometriosis

Sep. 3, 2001

Tostrelle shows promise as treatment for female sexual dysfunction

Sep. 3, 2001

Phase I trial of Herzyme commences in breast and ovarian cancer

Sep. 3, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...